1. WHO. New hepatitis data highlight need for urgent global response. 2018.
2. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. [Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]. Zhonghua Gan Zang Bing Za Zhi. 2022 Dec 20;30(12):1309-1331. Chinese. doi: 10.3760/cma.j.cn501113-20221204-00607. PMID: 36891718.
3. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase;Hui;Hepatology,2007
4. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-398. dio:10.1016/j.jhep.2017.03.021.
5. Stanniocalcin 1 is a serum biomarker and potential therapeutic target for HBV-associated liver fibrosis;Chan;J. Pathol.,2022